This program will discuss Preventive Cardiology. Learners will familiarize themselves with the AHA PREVENT risk scoring model, which has replaced the prior Pooled Cohort Equations-based model in atherosclerotic cardiovascular disease (ASCVD) risk prediction. Risk-based decisions regarding performance of additional atherosclerotic screening tools and treatment decisions will be examined. Lipid-lowering therapy goals are based on the risk estimate informed by demographic factors, laboratory testing, and imaging (e.g. coronary artery calcium score) results. This presentation reviews the literature surrounding lipoprotein(a) (Lp(a)) as a cardiovascular risk factor, including its genetic determinants, structure, and atherogenic mechanisms. Learners will explore the atherogenic mechanisms of Lp(a), its genetic determinants, along with contemporary and future management strategies for elevated Lp(a). The talk will also address the evolving role of aspirin in primary prevention, and the use of high-sensitivity C-reactive protein (hsCRP) in assessing atherosclerotic cardiovascular disease (ASCVD) risk.

Link to transcript

[Link to transcript](https://podcast.osu.edu/osumednet21/wp-content/uploads/sites/27/2026/05/PreventiveCardiology_transcript.pdf)